Recursion Pharmaceuticals Inc - Class A (RXRX) Quality Analysis

RXRX GoodMoat Verdict

Full signal breakdown coming soon. Use the X-Ray tool for a detailed analysis.

Run Stock X-Ray →

RXRX Profitability

Profitability trend analysis coming soon

RXRX Growth

Growth trend analysis coming soon

RXRX Financial Health

Financial health indicators coming soon

RXRX Quality & Fundamental Analysis

Recursion Pharmaceuticals Inc - Class A (RXRX) is a Healthcare company in the Biotechnology industry, listed on NASDAQ. This quality analysis page evaluates Recursion Pharmaceuticals Inc - Class A's financial health using the Piotroski F-Score methodology, profitability ratios, growth trajectory, and balance sheet strength.

Recursion Pharmaceuticals Inc - Class A has a Piotroski F-Score of N/A out of 9, measuring profitability, leverage, and operating efficiency. The company operates with a profit margin of -842.93% and a return on equity (ROE) of -49.50%. Return on assets (ROA) stands at -37.97%.

The debt-to-equity ratio is 0.07, with a current ratio of 5.50. Operating margin is -867.87%.

GoodMoat's quality analysis uses AI-powered insights to evaluate whether Recursion Pharmaceuticals Inc - Class A is a fundamentally sound investment. The GoodMoat Verdict synthesizes profitability, growth, and financial health scores into a clear investment quality rating. Use these metrics alongside valuation tools like the DCF calculator and fair value models to make informed investment decisions.